Edwin Lee
Lawyers
Filters
Venus Medtech (Hangzhou) HK$1.2 billion H shares placement
Davis Polk advised Venus Medtech (Hangzhou) Inc. in connection with its placing of 18,500,000 new H shares for an aggregate consideration of approximately HK$1.2 billion (approximately US…
Akeso HK$2.44 billion IPO
Davis Polk advised the underwriters in the initial public offering and listing on the Hong Kong Stock Exchange and the international offering in reliance on Rule 144A and Regulation S…
Tianfeng Securities $100 million notes offering
Davis Polk advised Tianfeng Securities Co., Ltd. in connection with its $100 million notes offering. The notes will be consolidated and form a single series with the $200 million notes…
Zai Lab $300 million follow-on offering of ADSs
Davis Polk advised Zai Lab Limited in connection with its follow-on offering of approximately $300 million of American depositary shares, representing 5,500,000 ordinary shares by the…
Davis Polk Advises Venus Medtech (Hangzhou) Inc. on Its HK$2.59 Billion (US$331.17 Million) Initial Public Offering
Davis Polk advised Venus Medtech (Hangzhou) Inc. in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in reliance on Rule…
Davis Polk Advised China International Capital Corporation Limited on Its Placing of New H Shares
Davis Polk advised China International Capital Corporation Limited in connection with its placing of 176,000,000 new H shares at a total consideration of approximately HK$2.5 billion …
China Aoyuan Group Limited $225 Million High-Yield Senior Notes Offering
Davis Polk advised the initial purchasers in connection with a $225 million Regulation S only high-yield offering by China Aoyuan Group Limited of its 7.95% senior notes due 2023.
China…